TN2009000095A1 - Thiazole pyrazolopyrimidines as crf1 receptor antagonists - Google Patents

Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Info

Publication number: TN2009000095A1
Authority: TN; Tunisia
Prior art keywords: receptor antagonists; crf1 receptor; pyrazolopyrimidines; thiazole; thiazole pyrazolopyrimidines
Prior art date: 2006-09-20

Application number

TN2009000095A

Other languages

English (en)

Inventor

Zhaogen Chen

Chafiq Hamdouchi Hamdouchi

Erik James Hembre

Philip Arthur Hipskind

Jason Kenneth Myers

Takako Takakuwa

James Lee Toth

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-20

Filing date

2009-03-19

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38924802&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000095(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-19 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-08-19 Publication of TN2009000095A1 publication Critical patent/TN2009000095A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Urology & Nephrology (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

TN2009000095A 2006-09-20 2009-03-19 Thiazole pyrazolopyrimidines as crf1 receptor antagonists TN2009000095A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82626406P	2006-09-20	2006-09-20
PCT/US2007/078605 WO2008036579A1 (fr)	2006-09-20	2007-09-17	Thiazole pyrazolopyrimidines convenant comme antagonistes du récepteur du crf1

Publications (1)

Publication Number	Publication Date
TN2009000095A1 true TN2009000095A1 (en)	2010-08-19

Family

ID=38924802

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000095A TN2009000095A1 (en)	2006-09-20	2009-03-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists

Country Status (33)

Country	Link
US (1)	US8030304B2 (fr)
EP (1)	EP2094709B1 (fr)
JP (1)	JP5161226B2 (fr)
KR (1)	KR101088239B1 (fr)
CN (1)	CN101516887B (fr)
AR (1)	AR062886A1 (fr)
AT (1)	ATE481405T1 (fr)
AU (1)	AU2007297421B2 (fr)
BR (1)	BRPI0717023B8 (fr)
CA (1)	CA2663511C (fr)
CL (1)	CL2007002693A1 (fr)
CR (1)	CR10682A (fr)
CY (1)	CY1110854T1 (fr)
DE (1)	DE602007009305D1 (fr)
DK (1)	DK2094709T3 (fr)
EA (1)	EA015179B1 (fr)
ES (1)	ES2350282T3 (fr)
HR (1)	HRP20100516T1 (fr)
IL (1)	IL197614A (fr)
MA (1)	MA30798B1 (fr)
MX (1)	MX2009003125A (fr)
MY (1)	MY146388A (fr)
NO (1)	NO20091489L (fr)
NZ (1)	NZ575572A (fr)
PE (1)	PE20081377A1 (fr)
PL (1)	PL2094709T3 (fr)
PT (1)	PT2094709E (fr)
RS (1)	RS51545B (fr)
SI (1)	SI2094709T1 (fr)
TN (1)	TN2009000095A1 (fr)
TW (1)	TWI402269B (fr)
UA (1)	UA96458C2 (fr)
WO (1)	WO2008036579A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2025674A1 (fr)	2007-08-15	2009-02-18	sanofi-aventis	Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2010039678A1 (fr) *	2008-10-02	2010-04-08	Eli Lilly And Company	Composés de thiazolylpyrazolopyrimidine à usage d'intermédiaires de synthèse et procédés de synthèse associés
EP2567959B1 (fr)	2011-09-12	2014-04-16	Sanofi	Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
US20170020877A1 (en)	2014-01-21	2017-01-26	Neurocrine Biosciences, Inc.	Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
PL236355B1 (pl) *	2015-04-02	2021-01-11	Celon Pharma Spolka Akcyjna	Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
CN109906222B (zh)	2016-09-07	2023-08-01	加利福尼亚大学董事会	减少p-tau并且改善认知的变构促肾上腺皮质激素释放因子受体1(crfr1)拮抗剂
CN110996943A (zh)	2017-08-14	2020-04-10	云杉生物科学公司	促肾上腺皮质激素释放因子受体拮抗剂
WO2019036472A1 (fr) *	2017-08-14	2019-02-21	Spruce Biosciences, Inc.	Antagonistes du récepteur du facteur de libération de la corticotropine
CA3098562A1 (fr)	2018-04-27	2019-10-31	Spruce Biosciences, Inc.	Methodes de traitement de tumeurs des vertiges surrenaliens des testicules et des ovaires
CN109134481B (zh) *	2018-08-07	2021-05-14	中山大学	一种取代吡咯色原酮类化合物或其药学上可接受的盐及其制备方法和应用
TWI714231B (zh) *	2018-09-04	2020-12-21	美商美國禮來大藥廠	2,6-二胺基吡啶化合物
WO2020115555A2 (fr)	2018-12-07	2020-06-11	Neurocrine Biosciences, Inc.	Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale
MX2022000812A (es) *	2019-07-19	2022-02-16	Spruce Biosciences Inc	Metodos de tratamiento de hiperplasia suprarrenal congenita.
US12383536B2 (en)	2019-09-27	2025-08-12	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods of use
ES3039926T3 (en) *	2019-12-04	2025-10-27	Neurocrine Biosciences Inc	Crf receptor antagonists and methods of use
GR1010096B (el) *	2020-07-02	2021-10-08	Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε,	Πυραζολο[1,5-a]πυριμιδινες με δραση αναστολης της αυτοταξινης
CA3188730A1 (fr) *	2020-08-12	2022-02-17	Christopher Barnes	Procedes et compositions pour traiter le syndrome des ovaires polykystiques
EP4203964A1 (fr)	2020-08-26	2023-07-05	Neurocrine Biosciences, Inc.	Antagonistes du récepteur crf et méthodes d'utilisation
CA3211644A1 (fr)	2021-03-19	2022-09-22	Christine FERRARA-COOK	Antagoniste du recepteur du sous-type 2 de la melanocortine (mc2r) pour le traitement d'une maladie
EP4402142A4 (fr) *	2021-11-19	2025-07-23	Spruce Biosciences Inc	Composition cristalline de tildacerfont et ses méthodes d'utilisation et de préparation
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
WO2023163945A1 (fr) *	2022-02-23	2023-08-31	Crinetics Pharmaceuticals, Inc.	Traitement de l'hyperplasie surrénale congénitale et du syndrome des ovaires polykystiques
WO2025188842A1 (fr) *	2024-03-08	2025-09-12	Spruce Biosciences, Inc.	Dispersion solide amorphe de formulations de tildacerfont

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0674641T3 (da)	1992-12-17	1999-09-27	Pfizer	Pyrrolopyrimidiner som CRF-antagonister
NZ330119A (en) *	1996-02-07	2000-02-28	Janssen Pharmaceutica Nv	Pyrazolopyrimidines as crf receptor antagonists
WO1998003510A1 (fr) *	1996-07-24	1998-01-29	Du Pont Pharmaceuticals Company	Azolo triazines et pyrimidines
CN1104432C (zh) *	1996-07-24	2003-04-02	杜邦药品公司	吡咯并三嗪和嘧啶化合物
EP0923582B1 (fr)	1996-08-28	2006-09-20	Pfizer Inc.	Derives 6,5-hetero-bicycliques substitues
EP1040831A3 (fr) *	1999-04-02	2003-05-02	Pfizer Products Inc.	Utilisation d'antagonistes du facteur de libération de la corticotropine pour la prévention de la mort subite
AU4203500A (en)	1999-04-06	2000-10-23	Du Pont Pharmaceuticals Company	Pyrazolopyrimidines as crf antagonists
HUP0203131A3 (en) *	1999-09-30	2004-06-28	Pfizer	Amino substituted pyrazolo[1,5-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
DE60218434T2 (de) *	2001-03-13	2007-11-08	Bristol-Myers Squibb Pharma Co.	4-(2-BUTYLAMINO)-2,7-DIMETHYL-8-(2-METHYL-6-METHOXYPYRID-3-YL) PYRAZOLO- 1,5-Aö-1,3,5-TRIAZIN, SEINE ENANTIOMEREN UND PHARMAZEUTISCH ANNEHMBARE SALZE ALS CORTICOTROPIN-RELEASING-FACTOR-REZEPTOR-LIGANDEN
AR046967A1 (es)	2003-12-22	2006-01-04	Sb Pharmco Inc	Compuesto de pirazol[1,5-a]pirimidina, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion

2007
- 2007-09-17 US US12/377,733 patent/US8030304B2/en active Active
- 2007-09-17 JP JP2009529316A patent/JP5161226B2/ja active Active
- 2007-09-17 NZ NZ575572A patent/NZ575572A/en not_active IP Right Cessation
- 2007-09-17 AU AU2007297421A patent/AU2007297421B2/en not_active Ceased
- 2007-09-17 PL PL07842582T patent/PL2094709T3/pl unknown
- 2007-09-17 DK DK07842582.4T patent/DK2094709T3/da active
- 2007-09-17 ES ES07842582T patent/ES2350282T3/es active Active
- 2007-09-17 AT AT07842582T patent/ATE481405T1/de active
- 2007-09-17 EA EA200970303A patent/EA015179B1/ru active IP Right Revival
- 2007-09-17 KR KR1020097005602A patent/KR101088239B1/ko not_active Expired - Fee Related
- 2007-09-17 CA CA2663511A patent/CA2663511C/fr active Active
- 2007-09-17 UA UAA200902216A patent/UA96458C2/ru unknown
- 2007-09-17 RS RSP-2010/0517A patent/RS51545B/sr unknown
- 2007-09-17 CN CN2007800351453A patent/CN101516887B/zh active Active
- 2007-09-17 MX MX2009003125A patent/MX2009003125A/es active IP Right Grant
- 2007-09-17 EP EP07842582A patent/EP2094709B1/fr active Active
- 2007-09-17 WO PCT/US2007/078605 patent/WO2008036579A1/fr not_active Ceased
- 2007-09-17 DE DE602007009305T patent/DE602007009305D1/de active Active
- 2007-09-17 MY MYPI20091067A patent/MY146388A/en unknown
- 2007-09-17 HR HR20100516T patent/HRP20100516T1/hr unknown
- 2007-09-17 SI SI200730435T patent/SI2094709T1/sl unknown
- 2007-09-17 PT PT07842582T patent/PT2094709E/pt unknown
- 2007-09-17 BR BRPI0717023A patent/BRPI0717023B8/pt active IP Right Grant
- 2007-09-18 AR ARP070104125A patent/AR062886A1/es active IP Right Grant
- 2007-09-20 TW TW096135177A patent/TWI402269B/zh not_active IP Right Cessation
- 2007-09-20 CL CL200702693A patent/CL2007002693A1/es unknown
- 2007-09-20 PE PE2007001271A patent/PE20081377A1/es not_active Application Discontinuation
2009
- 2009-03-16 IL IL197614A patent/IL197614A/en active IP Right Grant
- 2009-03-19 TN TN2009000095A patent/TN2009000095A1/fr unknown
- 2009-03-20 CR CR10682A patent/CR10682A/es not_active Application Discontinuation
- 2009-04-16 MA MA31794A patent/MA30798B1/fr unknown
- 2009-04-16 NO NO20091489A patent/NO20091489L/no not_active Application Discontinuation
2010
- 2010-10-21 CY CY20101100946T patent/CY1110854T1/el unknown

Also Published As

Publication number	Publication date
EA200970303A1 (ru)	2009-10-30
MX2009003125A (es)	2009-05-28
HRP20100516T1 (hr)	2010-10-31
PE20081377A1 (es)	2008-09-18
IL197614A0 (en)	2009-12-24
US8030304B2 (en)	2011-10-04
AU2007297421B2 (en)	2012-03-08
EP2094709B1 (fr)	2010-09-15
BRPI0717023B8 (pt)	2021-05-25
DK2094709T3 (da)	2010-12-06
BRPI0717023A2 (pt)	2014-03-11
TW200821312A (en)	2008-05-16
BRPI0717023B1 (pt)	2019-11-19
CN101516887B (zh)	2011-11-02
CA2663511C (fr)	2012-12-04
CR10682A (es)	2009-08-13
CY1110854T1 (el)	2015-06-10
NZ575572A (en)	2011-10-28
DE602007009305D1 (de)	2010-10-28
JP5161226B2 (ja)	2013-03-13
KR20090052366A (ko)	2009-05-25
EA015179B1 (ru)	2011-06-30
IL197614A (en)	2012-10-31
CA2663511A1 (fr)	2008-03-27
CL2007002693A1 (es)	2008-04-18
SI2094709T1 (sl)	2011-01-31
EP2094709A1 (fr)	2009-09-02
TWI402269B (zh)	2013-07-21
ES2350282T3 (es)	2011-01-20
RS51545B (sr)	2011-06-30
MA30798B1 (fr)	2009-10-01
US20100222339A1 (en)	2010-09-02
MY146388A (en)	2012-08-15
JP2010504344A (ja)	2010-02-12
UA96458C2 (ru)	2011-11-10
AU2007297421A1 (en)	2008-03-27
CN101516887A (zh)	2009-08-26
PL2094709T3 (pl)	2011-02-28
HK1132505A1 (en)	2010-02-26
ATE481405T1 (de)	2010-10-15
KR101088239B1 (ko)	2011-11-30
PT2094709E (pt)	2010-10-04
AR062886A1 (es)	2008-12-10
NO20091489L (no)	2009-04-16
WO2008036579A1 (fr)	2008-03-27

Publication	Publication Date	Title
TN2009000095A1 (en)	2010-08-19	Thiazole pyrazolopyrimidines as crf1 receptor antagonists
MX2009003098A (es)	2009-04-01	Compuestos de tiofen pirazolopirimidina.
CY1109069T1 (el)	2014-07-02	Ενωσεις ιμιδαζοπυριδαζινης
MX2020012868A (es)	2022-06-14	Metodos y composiciones para trastornos del sue?o y otros trastornos.
DK1951729T3 (da)	2014-10-06	Oxygenbundne pyrimidinderivater
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
GB0625648D0 (en)	2007-01-31	Compounds
EA200602062A1 (ru)	2007-04-27	Амидосоединения и их применение в качестве фармацевтических средств
SG170828A1 (en)	2011-05-30	Deazapurines useful as inhibitors of janus kinases
ZA201100526B (en)	2012-04-25	Triazolo [4,5-d]pyramidine derivatives and their use as purine receptor antagonists
MX2009005398A (es)	2009-08-20	Metodos para el tratamiento de enfermedades inflamatorias cronicas usando antagonista de gm-csf.
WO2008045564A8 (fr)	2008-07-17	Composés de carboxamide et leur utilisation
MX2009010127A (es)	2009-11-05	Compuestos utiles como inhibidores de janus cinasas.
GEP20135927B (en)	2013-10-10	1-benzyl-3-hydroxymethylindaz-ole derivatives and usage thereat treatment of diseases based on mcp-1, cx3cr1 and p40 expression
CL2007000789A1 (es)	2008-01-18	Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer.
DE602007007934D1 (en)	2010-09-02	Imidazoazephinonverbindungen
WO2005094798A3 (fr)	2006-04-13	Compositions pharmaceutiques a base d'anticholinergiques et d'antagonistes du recepteur ccr2
WO2006138589A3 (fr)	2009-04-16	Ligands de recepteur opioide
UA94028C2 (ru)	2011-04-11	Амидосоединения и их применение в качестве лекарственных средств